New England Journal of Medicine (2025) The REDEFINE 1 Phase 3 trial was a landmark 68-week, double-blind, randomized study comparing CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with semaglutide alone, cagrilintide alone, and placebo in 3,417 adults with obesity or overweight without diabetes
(PubMed) Mazokopakis EE, Starakis IK
1 x Diamond Serum
RNA (2 g) was reverse transcribed to cDNA using the SuperScript II RNase H-reverse transcriptase system (Invitrogen, Carlsbad, CA, USA)
What They Found 31.2% of human genes affected by GHK-Cu Gene expression analysis revealed that GHK-Cu influences 31.2% of all human genes with a change of 50% an exceptionally broad biological effect
Medications that inhibit these enzymes (like certain blood pressure medications) may alter DSIP metabolism